Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
146 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2014', provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Adenocarcinoma Of The Gastroesophageal Junction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Adenocarcinoma Of The Gastroesophageal Junction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Adenocarcinoma Of The Gastroesophageal Junction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Adenocarcinoma of the Gastroesophageal Junction Overview 9 Therapeutics Development 10 Pipeline Products for Adenocarcinoma of the Gastroesophageal Junction - Overview 10 Pipeline Products for Adenocarcinoma of the Gastroesophageal Junction - Comparative Analysis 11 Adenocarcinoma of the Gastroesophageal Junction - Therapeutics under Development by Companies 12 Adenocarcinoma of the Gastroesophageal Junction - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Adenocarcinoma of the Gastroesophageal Junction - Products under Development by Companies 17 Adenocarcinoma of the Gastroesophageal Junction - Companies Involved in Therapeutics Development 19 AlphaMab Co., Ltd 19 Amgen Inc. 20 Apceth GmbH & Co. KG 21 ArQule, Inc. 22 AstraZeneca PLC 23 Boehringer Ingelheim GmbH 24 Boston Biomedical, Inc. 25 Bristol-Myers Squibb Company 26 Cerulean Pharma, Inc. 27 Eli Lilly and Company 28 Epirus Biopharmaceuticals, Inc. 29 F. Hoffmann-La Roche Ltd. 30 Ganymed Pharmaceuticals AG 31 Genentech, Inc. 32 Mebiopharm Co., Ltd. 33 Merck & Co., Inc. 34 Millennium Pharmaceuticals, Inc. 35 Novartis AG 36 Panacea Biotec Limited 37 Sanofi 38 Supratek Pharma Inc. 39 Adenocarcinoma Of the Gastroesophageal Junction - Therapeutics Assessment 40 Assessment by Monotherapy Products 40 Assessment by Target 41 Assessment by Mechanism of Action 43 Assessment by Route of Administration 45 Assessment by Molecule Type 47 Drug Profiles 49 Agenmestencel-T - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 AMG-337 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 AZD-4547 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 BBI-608 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 BI-853520 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 BMS-833923 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 cabazitaxel - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 CRLX-101 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 dovitinib lactate - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 doxorubicin - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 emibetuzumab - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 erismodegib - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 IMAB-362 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 ipatasertib - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 MBP-426 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 MLN-0264 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 panitumumab - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 pembrolizumab - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 ramucirumab - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 rilotumumab - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 solitomab - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 tivantinib - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 trastuzumab biosimilar - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 trastuzumab biosimilar - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 trastuzumab biosimilar - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 trastuzumab biosimilar - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 trastuzumab emtansine - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 trebananib - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 Adenocarcinoma Of the Gastroesophageal Junction - Recent Pipeline Updates 108 Adenocarcinoma Of the Gastroesophageal Junction - Dormant Projects 142 Adenocarcinoma Of the Gastroesophageal Junction - Discontinued Products 143 Adenocarcinoma Of the Gastroesophageal Junction - Product Development Milestones 144 Featured News & Press Releases 144 Jul 22, 2014: Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer 144 Appendix 145 Methodology 145 Coverage 145 Secondary Research 145 Primary Research 145 Expert Panel Validation 145 Contact Us 146 Disclaimer 146
List of Tables Number of Products under Development for Adenocarcinoma of the Gastroesophageal Junction, H2 2014 10 Number of Products under Development for Adenocarcinoma of the Gastroesophageal Junction - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Comparative Analysis by Late Stage Development, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Products under Development by Companies, H2 2014 17 Products under Development by Companies, H2 2014 (Contd..1) 18 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by AlphaMab Co., Ltd, H2 2014 19 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Amgen Inc., H2 2014 20 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Apceth GmbH & Co. KG, H2 2014 21 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by ArQule, Inc., H2 2014 22 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by AstraZeneca PLC, H2 2014 23 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H2 2014 24 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H2 2014 25 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H2 2014 26 Adenocarcinoma Of the Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H2 2014 27 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H2 2014 28 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 29 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 30 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H2 2014 31 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Genentech, Inc., H2 2014 32 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H2 2014 33 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H2 2014 34 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 35 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Novartis AG, H2 2014 36 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H2 2014 37 Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Sanofi, H2 2014 38 Adenocarcinoma Of the Gastroesophageal Junction - Pipeline by Supratek Pharma Inc., H2 2014 39 Assessment by Monotherapy Products, H2 2014 40 Number of Products by Stage and Target, H2 2014 42 Number of Products by Stage and Mechanism of Action, H2 2014 44 Number of Products by Stage and Route of Administration, H2 2014 46 Number of Products by Stage and Molecule Type, H2 2014 48 Adenocarcinoma Of the Gastroesophageal Junction Therapeutics - Recent Pipeline Updates, H2 2014 108 Adenocarcinoma Of the Gastroesophageal Junction - Dormant Projects, H2 2014 142 Adenocarcinoma Of the Gastroesophageal Junction - Discontinued Products, H2 2014 143
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.